- $634.05m
- $592.59m
- $34.85m
- 73
- 10
- 71
- 50
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 23 | 24 | 26.5 | 30.2 | 34.9 |
Cost of Revenue | |||||
Gross Profit | 15 | 16.1 | 17.7 | 14.3 | 19.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 56.7 | 56.8 | 61.3 | 92 | 83.1 |
Operating Profit | -33.7 | -32.8 | -34.8 | -61.8 | -48.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -32.8 | -32.5 | -34.7 | -59.7 | -45.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -32.8 | -32.5 | -34.8 | -59.8 | -46 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -32.8 | -32.5 | -34.8 | -59.8 | -46 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -32.8 | -44 | -34.8 | -59.8 | -46 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.79 | -3.41 | -2.26 | -3.09 | -2.25 |